Formic Acid → Clarithromycin formate

HRID 1278901

Reaktionsgleichung

[CH3:1][CH2:2][C@H:3]1[O:18][C:16](=[O:17])[C@H:15]([CH3:19])[C@@H:14]([O:20][C@@H:21]2[O:26][C@@H:25]([CH3:27])[C@H:24]([OH:28])[C@@:23]([O:30][CH3:31])([CH3:29])[CH2:22]2)[C@H:13]([CH3:32])[C@@H:12]([O:33][C@@H:34]2[O:39][C@H:38]([CH3:40])[CH2:37][C@H:36]([N:41]([CH3:43])[CH3:42])[C@H:35]2[OH:44])[C@@:11]([O:46][CH3:47])([CH3:45])[CH2:10][C@@H:9]([CH3:48])[C:7](=[O:8])[C@H:6]([CH3:49])[C@@H:5]([OH:50])[C@@:4]1([OH:52])[CH3:51].[CH:53]([OH:55])=[O:54]>CC(C)=O>[CH3:1][CH2:2][C@H:3]1[O:18][C:16](=[O:17])[C@H:15]([CH3:19])[C@@H:14]([O:20][C@@H:21]2[O:26][C@@H:25]([CH3:27])[C@H:24]([OH:28])[C@@:23]([O:30][CH3:31])([CH3:29])[CH2:22]2)[C@H:13]([CH3:32])[C@@H:12]([O:33][C@@H:34]2[O:39][C@H:38]([CH3:40])[CH2:37][C@H:36]([N:41]([CH3:42])[CH3:43])[C@H:35]2[OH:44])[C@@:11]([O:46][CH3:47])([CH3:45])[CH2:10][C@@H:9]([CH3:48])[C:7](=[O:8])[C@H:6]([CH3:49])[C@@H:5]([OH:50])[C@@:4]1([OH:52])[CH3:51].[CH:53]([O-:55])=[O:54]

Komponenten

Reaktionsbedingungen

Temperatur: 0 °C

Versuchsvorschrift

7.48 g of clarithromycin (purity: 95.4%) was suspended in 70 ml of acetone, and 0.49 ml of formic acid was added thereto and refluxed for 30 minutes. The suspension was cooled to 0° C. and stirred for 2 hours. Then, the resulting crystals were filtered, washed with cold acetone and dried to give 7.42 g of clarithromycin formate (purity: 97.9%, yield: 94%).

Aufarbeitung

temperaturerefluxed for 30 minutes
filtrationThen, the resulting crystals were filtered
washwashed with cold acetone
customdried

Quellen und Nachweise

ORD-Eintrag: ord-7c081f6e3c264ea492fd1a7e61037172
Quelldatensatz: uspto-grants-2002_09
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US06444796B1

Verknüpfte Notizen

Wird geladen…